#TScan
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526424198/0001193125-26-424198-index.htm
October 16, 2026 at 8:55 PM
🚨 $TCRX
Resignation of Garry Nicholson and Gabriela Gruia, M.D. On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors of TScan Therapeutics, Inc. and each committee thereof, in each case effective as of October 13, 2026 . Neither Mr. Nicholson...
SEC Filing: TCRX
Click to view the official SEC document.
www.sec.gov
October 16, 2026 at 8:45 PM
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526409199/0001193125-26-409199-index.htm
September 30, 2026 at 9:22 PM
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
September 11, 2026 at 2:00 PM
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
September 11, 2026 at 12:16 PM
🚨 $TCRX
On September 8, 2026, the Compensation Committee of the Board of Directors of TScan Therapeutics, Inc. approved a retention program designed to retain the employees required to support the Company, including a key employee retention program that provides for cash awards and the potential ...
SEC Filing: TCRX
Click to view the official SEC document.
www.sec.gov
September 11, 2026 at 12:01 PM
TScan Therapeutics $TCRX: HC Wainwright & Co. downgraded from Buy to Neutral and lowered its price target from $7.00 to $1.00.

https://fundspec.ai/s/TCRX/analysts
Draw trendlines and run technical studies on pro grade charts.
September 8, 2026 at 3:15 PM
TScan is pausing its Phase 3 TSC-101 trial and cutting approximately 75% of its workforce in a major strategic reset.

Follow Us for More!

Disclaimer: This is NOT a financial advice
September 8, 2026 at 7:13 AM
Needham Downgrades TScan Therapeutics to Hold From Buy
finwires.com
September 3, 2026 at 4:01 AM
TScan is latest cell therapy developer to pivot into in vivo #$TCRX firstwordpharma.com/story/7941531
September 2, 2026 at 10:01 PM
TScan Therapeutics Cuts 75% of Workforce, Pivots to Solid Tumors: TScan Therapeutics is reorganizing to prioritize an in vivo solid tumor program, cutting roughly 75% of its workforce and pausing enrollment in its Phase 3 ALLOHA-2 trial due to limited capital. The… #MarketUpdates Follow Us for more
TScan Therapeutics Cuts 75% of Workforce, Pivots to Solid Tumors
TScan Therapeutics is reorganizing to prioritize an in vivo solid tumor program, cutting roughly 75% of its workforce and pausing enrollment in its Phase 3 ALLOHA-2 trial due to limited capital. The restructuring is expected to save $55 million through 2027 and extend the company's cash runway into the fourth quarter of 2027.
quantli.com
September 2, 2026 at 10:19 PM
#$TCRX is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027. notreload.xyz/xy/tcrx-pivo...
TScan Pivots to In Vivo T-Cell Therapy, Cuts 75% of Staff
TScan is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027.
notreload.xyz
September 2, 2026 at 1:40 PM
TScan Therapeutics, Inc. (0001783328) (Filer) (cik: 0001783328) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/0001193125-26-379343-index.htm
September 2, 2026 at 11:35 AM
#TCRX TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

https://www.stocktitan.net/news/TCRX/t-scan-therapeutics-announces-strategic-reorganization-to-focus-on-5dn3kehaphte.html
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics (TCRX) announced a strategic reorganization to prioritize its in vivo-engineered TCR-T solid tumor program, advancing two candidates targeting PRAME and MAGE-A4 into IND-enabling studies.The company plans to share preclinical data in Q1 2027, file its first IND in Q3 2027, and initiate Phase 1 development in Q4 2027. Updated Phase 1 ALLOHA™ Cohort C data for TSC-101 in heme malignancies show 100% (13/13) of tracked patients with complete donor chimerism, with infusions generally well tolerated. Due to capital constraints, TScan has paused further enrollment in the Phase 3 ALLOHA-2™ study and is pausing the heme malignancies program while seeking partners. The reorganization includes eliminating internal manufacturing, reducing research footprint, and a workforce reduction of approximately 75%, targeting cumulative cost savings of $55 million through 2027 and extending cash runway into Q4 2027.
www.stocktitan.net
September 2, 2026 at 11:00 AM
🔴 #$TCRX — Clinical Milestone
Phase 3 ALLOHA-2 Enrollment Paused; Heme Malignancies Program Paused Due to Capital Constraints
TScan announced a strategic reorganization prioritizing its in vivo solid tumor program, pausing further enrollment in the pivotal Phas…

https://biostock.app/symbols/TCRX
September 2, 2026 at 11:26 AM